N-Benzylpiperazino derivatives of 3-nitro-4-hydroxycoumarin with H1 antihistamine and mast cell stabilizing properties
摘要:
In a small range finding study a number of N-benzylpiperazino derivates of 3-nitro-4-hydroxycoumarin have been shown to combine potent H1-antihistamine activity with that of mast cell stabilization as demonstrated by their activity as antagonists of histamine on guinea pig ileum and by their inhibition of the release of histamine in rat passive peritoneal anaphylaxis (PPA). The most potent compound, 1-[2-hydroxy-3-[(4-hydroxy-3-nitrocoumarin-7-yl)oxy]propyl]-4- (4-chlorobenzyl)piperazine, 30, had a pA2 of 9.0 against histamine on guinea pig ileum and inhibited histamine release in the rat PPA test with a potency similar to that of disodium cromoglycate.
A compound of formula (I): ##STR1## and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is --(CH.sub.2).sub.n -- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema.
Heterocyclic coumarin derivatives, their preparation and pharmaceutical compositions comprising said derivatives
申请人:BEECHAM GROUP PLC
公开号:EP0010392A1
公开(公告)日:1980-04-30
A compound of formula (I):
and pharmaceutically acceptable salts thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a bond or oxygen; Y is -(CH2)n -where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen; e.g. 1-(4-chlorobenzyl) -4-[3-(4-hydroxy-3-nitro- coumarin-7-yloxy) propyl] piperazine; may be used in the prophylaxis and treatment of diseases whose symptoms are controlled by the mediators of the allergic response, for example asthma, hay-fever, rhinitis and allergic eczema.
A compound of formula (I) is prepared by reacting a compound of formula (II) or a salt thereof
wherein R, X, Y, and Z are defined with respect to formula (i) with a nitrating agent
式(I)化合物
及其药学上可接受的盐类,其中 R 是氢或最多含有 6 个碳原子的烷基;X 是键或氧;Y 是-(CH2)n -其中 n 是 0 或 1 至 5 的整数,其中未与氮原子结合的一个碳原子可任选被羟基取代;Z 是氢或卤素;例如:1-(4-氯苄基)-4-[3-(4-羟基-3-硝基香豆素-7-氧基)丙基]哌啶。g. 1-(4-氯苄基)-4-[3-(4-羟基-3-硝基香豆素-7-氧基)丙基]哌嗪;可用于预防和治疗其症状受过敏反应介质控制的疾病,例如哮喘、花粉症、鼻炎和过敏性湿疹。
式(I)化合物是通过式(II)化合物或其盐反应制备的
其中 R、X、Y 和 Z 的定义见式 (i)。
Coumarin intermediates
申请人:BEECHAM GROUP PLC
公开号:EP0050396A1
公开(公告)日:1982-04-28
Compounds of the formula (II):
or a salt thereof, wherein R is hydrogen or an alkyl group containing up to 6 carbon atoms; X is a covalent bond or oxygen; Y is -(CH2)n- where n is 0 or an integer from 1 to 5 wherein one carbon atom not bound to the nitrogen atom may be optionally substituted with a hydroxy group; and Z is hydrogen or halogen are useful intermediates in the preparation of pharmacologically active compounds described in European Patent Application No 79302141.
式 (II) 的化合物:或其盐,其中 R 是氢或最多含有 6 个碳原子的烷基;X 是共价键或氧;Y 是-(CH2)n-,其中 n 是 0 或 1 至 5 的整数,其中未与氮原子结合的一个碳原子可任选被羟基取代;Z 是氢或卤素,是制备欧洲专利申请第 79302141 号所述药理活性化合物的有用中间体。
BUCKLE, D. R.;OUTRED, D. J.;SMITH, H.;SPICER, B. A., J. MED. CHEM., 1984, 27, N 11, 1452-1457
作者:BUCKLE, D. R.、OUTRED, D. J.、SMITH, H.、SPICER, B. A.